B
Grant

Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)

Nationwide

About

This Notice of Funding Opportunity (NOFO) encourages collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods, and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research and is appropriate for small teams applying an integrative approach to increase our understanding of and solve problems in biological, clinical, or translational science. This NOFO will support clinical trials that test functionality or validate performance in the chosen setting. This NOFO is not intended to support conventional clinical trials that lack translation as the primary motivation. Applications that propose phase III clinical trials in any area of research are not sought by and will not be supported through this NOFO. This NOFO does not support commercial production.

The Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional) program is designed for researchers and small teams applying multidisciplinary bioengineering approaches to solve biomedical problems. This grant encourages collaboration between life and physical sciences to integrate, optimize, validate, and accelerate the adoption of innovative tools, methods, and techniques in basic, translational, or clinical science. The program supports design-directed, developmental, discovery-driven, and hypothesis-driven research that addresses specific biological, clinical, or translational challenges. Notably, this NOFO permits clinical trials that test functionality or validate performance in chosen settings, though it is not intended for conventional clinical trials without translation as the primary motivation. Phase III clinical trials are not supported. Researchers should note that commercial production is not eligible for funding. Entrepreneurs and research teams developing breakthrough bioengineering solutions with clinical applications should consider applying. The program welcomes both domestic U.S. organizations and international collaborations, making it accessible to a broad range of innovative researchers seeking federal funding to advance biomedical science.

Funding Facts

● Applications open

Deadline

July 5, 2029

Award Amount

Up to $500K

Who can apply

City or township governmentsIndependent school districtsPublic housing authorities/Indian housing authoritiesSpecial district governmentsOthers (see text field entitled "Additional Information o...Native American tribal governments (Federally recognized)+9 more
Apply on Grants.gov

Last verified July 5, 2026 · Source: Grants.gov

Grant Details

Grant Amount

Up to $500K

Deadline

2029-07-05

Grant Type

federal

Application Cycle

Annual deadline (July 5, 2029)

Best For

Multidisciplinary research teams, bioengineering innovators, translational researchers, small teams applying integrative approaches to biomedical problems

Eligibility

Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

Frequently Asked Questions

Who is eligible for Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)?

Eligible applicants include U.S. domestic organizations and non-U.S. entities (foreign organizations) seeking to apply multidisciplinary bioengineering approaches to biomedical problems. Non-domestic components of U.S. organizations may participate, though foreign components as defined in the NIH Grants Policy Statement are not allowed. For comprehensive eligibility criteria, refer to Section III of the official Notice of Funding Opportunity (NOFO) on the NIH website.

How much funding does Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional) provide?

Funding ranges from N/A to $500,000 per grant award. The specific amount available may vary by funding cycle. Applicants should consult the official NOFO for current year funding information and budget guidelines.

How do I apply for Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)?

Applications should be submitted through the official NIH application portal (Grants.gov or eRA Commons). Visit the NIH Office of Extramural Research website to access the complete NOFO, detailed application instructions, submission deadlines, and required forms. The next deadline is July 5, 2029. Applicants are strongly encouraged to review the full NOFO and contact the program officer with questions before submitting.

What can Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional) funding be used for?

Funding supports multidisciplinary bioengineering research that integrates, optimizes, validates, translates, or accelerates adoption of tools, methods, and techniques for biomedical problems. Eligible research includes design-directed, developmental, discovery-driven, or hypothesis-driven projects in basic, translational, or clinical science. The program can support clinical trials that test functionality or validate performance in chosen settings, provided translation is the primary motivation. Commercial production is not supported, and Phase III clinical trials are not eligible.

Last updated: July 5, 2026